



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# HIV MONITORING QUARTERLY REPORT **FOR BRITISH COLUMBIA**

FOURTH QUARTER 2014

\* Please see foreword



BC Centre for Disease Control  
An agency of the Provincial Health Services Authority



First Nations Health Authority  
Health through wellness



fraserhealth



Interior Health  
For your whole life



island health



northern health  
the northern way of caring



How you want to be treated.



Promoting wellness. Ensuring care.



## Foreword

As part of the BC Centre for Excellence (BC-CFE) in HIV/AIDS's mandate to evaluate the outcomes of STOP HIV/AIDS programming in BC, we have developed quarterly HIV/AIDS monitoring reports. These reports provide up-to-date data on a variety of key HIV-related surveillance and treatment indicators. Selection of these indicators was achieved through a collaborative process with various Health Authority (HA) representatives. There are six reports in total, one for each HA and one for the province of BC as a whole. In addition, there is a technical report which explains how each HIV indicator is calculated. Data used in these reports come from the British Columbia Centre for Disease Control (BCCDC), MSP billings, hospitalization data from the Discharge Abstract Database, the Sunquest Laboratory database at the Provincial Public Health Microbiology and Reference Laboratory, Providence Health Care laboratory and the BC-CFE Drug Treatment Program (DTP) Database.

The objectives of these reports are to:

1. Provide timely HA-specific information on key HIV indicators which will guide and inform HIV leaders and innovators in the development of future HIV interventions and programs which will ultimately lead to decreasing the burden of HIV in BC. The indicators will reflect ongoing or past successful public health interventions and highlight areas in the HIV care spectrum which require further attention and support.
2. Highlight limitations in our current data due to incomplete or time lagged data and to develop future strategies to improve complete and timely data capture.

These reports are produced for the benefit of individual HA's. As such, we are enthusiastic about your involvement and cooperation regarding the development of these monitoring reports. Please forward your comments and queries to Irene Day, Director of Operations at the BC-CFE at [iday@cfenet.ubc.ca](mailto:iday@cfenet.ubc.ca).

*\* For Indicator 1, new figures (Figure 1.6 and 1.7 on page 13) have been added to 2014 Q4 report for the following: HIV Test Episodes for Non-prenatal Females in BC by HA and HIV Test Episodes for Males in BC by HA.*

*For Indicator 5 (page 22) and 9 (page 31), recent updates to the DTP database have allowed for more comprehensive information on HIV risk group category. As a result, 2014 Q4 data may differ significantly from preceding reports in terms of total numbers ascribed to each risk group.*

## List of Indicators

Indicator 1. Testing Episodes

Indicator 2. HIV Testing Rate

Indicator 3. New HIV Diagnoses

Indicator 4. Stage of HIV Infection at Diagnosis

Indicator 5. HIV Cascade of Care

Indicator 6. Programmatic Compliance Score (PCS)

Indicator 7. New Antiretroviral Starts

Indicator 8. CD4 Cell Count at ART Initiation

Indicator 9. Active and Inactive Drug Treatment Program Participants

Indicator 10. Antiretroviral Adherence Level

Indicator 11. Resistance Testing Results by Resistance Category

Indicator 12. AIDS-Defining Illness

Indicator 13. HIV-Related Mortality

# Table of Contents

## Acknowledgements and Contributions

### BC Provincial STOP Program:

#### A Note on Monitoring and Interpreting Hiv Indicators

##### **Indicator 1      Hiv Testing Episodes**

Figure 1.1      Hiv Test Episodes for BC, 2010 Q1–2014 Q4

Figure 1.2      Hiv Test Episodes for BC by Gender and Prenatal Status, 2010 Q1–2014 Q4

Figure 1.3      Hiv Test Episodes for BC by Age Category, 2010 Q1–2014 Q4

Figure 1.4      Point-of-Care Hiv Tests for BC, 2010 Q4–2014 Q4

Figure 1.5      Hiv Test Episodes by Health Authority for BC, 2010 Q1–2014 Q4

Figure 1.6      Hiv Test Episodes for Non-Prenatal Females in BC by Health Authority, 2010 Q1–2014 Q4

Figure 1.7      Hiv Test Episodes for Males in BC by Health Authority, 2010 Q1–2014 Q4

##### **Indicator 2      Hiv Testing Rates**

Figure 2.1      Rate of Hiv Testing for BC and Health Authorities, 2009–2014

Figure 2.2      Rate of Hiv Testing for BC by Gender, 2009–2014

Figure 2.3      Rate of Hiv Testing for BC by Age Category, 2009–2014

##### **Indicator 3      New Hiv Diagnoses**

Figure 3.1      New Hiv Diagnoses for BC, 2010 Q1–2014 Q4

Figure 3.2      New Hiv Diagnoses for BC by Gender, 2010 Q1–2014 Q4

Figure 3.3      New Hiv Diagnoses for BC by Age Category, 2010 Q1–2014 Q4

Figure 3.4      New Hiv Diagnoses for BC by Exposure Category, 2010 Q1–2014 Q2

Figure 3.5      New Hiv Diagnoses for BC by Health Authority, 2010 Q1–2014 Q4

##### **Indicator 4      Stage of Hiv Infection at Diagnosis**

Table 1      Staging Classifications of Infection at Time of Hiv Diagnosis Based on CDC Hiv Surveillance Case Definitions

Figure 4.1      Stage of Hiv Infection at Diagnosis for BC, 2010–2013

Figure 4.2      Stage of Hiv Infection at Diagnosis for BC by Gender, 2010–2013

Figure 4.3      Stage of Hiv Infection at Diagnosis for BC by Age Category, 2010–2013

Figure 4.4      Stage of Hiv Infection at Diagnosis for BC by Exposure Category, 2010–2013

##### **Indicator 5      Hiv Cascade of Care**

Figure 5.1      Estimated Cascade of Care for BC, 2014

Figure 5.2      Estimated Cascade of Care for BC by Gender, 2014

Figure 5.3	Estimated Cascade of Care for BC by Age Category, 2014
Figure 5.4	Estimated Cascade of Care for BC by MSM Status, 2014
Figure 5.5	Estimated Cascade of Care for BC by Age Category and MSM Status, 2014
Figure 5.6	Estimated Cascade of Care for BC by History of IDU, 2014
Figure 5.7	Estimated Cascade of Care for BC by Health Authority, 2014
<b>Indicator 6</b>	<b>Programmatic Compliance Score (PCS)</b>
Table 2	Probability of Mortality Based on the Programmatic Compliance Score
Figure 6.1	PCS Components for BC, 2013 Q1–2014 Q4 <ul style="list-style-type: none"> <li>First-Year CD4 Measurement</li> <li>First-Year VL measurement</li> <li>Baseline Resistance Testing</li> <li>Recommended Antiretroviral Therapy (ART)</li> <li>Baseline CD4 <math>\geq 200</math> cells/<math>\mu</math>L</li> <li>Suppression at 9 Months</li> </ul>
Figure 6.2	Historical Trends for PCS Score for BC, 2013 Q1–2014 Q4
<b>Indicator 7</b>	<b>New Antiretroviral Therapy Starts in BC</b>
Figure 7	BC-CfE Drug Treatment Program Enrollment: New Antiretroviral Participants for BC, 2013 Q1–2014 Q4
<b>Indicator 8</b>	<b>CD4 Cell Count at ART Initiation</b>
Figure 8	CD4 Cell Count at ART Initiation for BC, 2013 Q1–2014 Q4
<b>Indicator 9</b>	<b>Active and Inactive Drug Treatment Program (DTP) Participants</b>
Table 3	Distribution of People on ART in BC, 2014 Q4
Figure 9	Active and Inactive DTP Participants for BC, 2013 Q1–2014 Q4
<b>Indicator 10</b>	<b>Antiretroviral Adherence</b>
Figure 10	Distribution of Individuals by Adherence Level in 1st Year of Therapy, Based on Pharmacy Refill Compliance for BC, 2013 Q1–2014 Q4
<b>Indicator 11</b>	<b>Resistance Testing and Results</b>
Figure 11	Cumulative Resistance Testing Results by Resistance Category for BC, 2013 Q1–2014 Q4
<b>Indicator 12</b>	<b>AIDS-Defining Illness</b>
Figure 12	AIDS Case Rate and Reports for BC, 2007–2014
<b>Indicator 13</b>	<b>HIV-Related Mortality</b>
Figure 13	HIV-Related Deaths by Year for BC, 2004–2011

# Acknowledgements and Contributions



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

**British Columbia Centre for Excellence in HIV/AIDS (BC-CFE):** The BC-CFE is responsible for the conception, preparation and ongoing review of this quarterly report. The BC-CFE provides the data and outputs for Indicators 5 (Hiv Cascade of Care), 6 (Programmatic Compliance Score), 7 (New Antiretroviral Starts), 8 (CD4 Cell Count at ART Initiation), 9 (Active and Inactive Drug Treatment Program Participants), 10 (Antiretroviral Adherence Level), 11 (Resistance Testing Results by Resistance Category), 12 (AIDS-Defining Illness), and 13 (HIV-Related Mortality). The BC-CFE database provides PVL and CD4 cell count testing data, as well as ART use. All PVL measurements in BC are performed at the St Paul's Hospital virology laboratory, thus PVL data capture is 100%. An estimated 80% of all CD4 count measurements performed in the province are captured in the BC-CFE data holdings. The STOP HIV/AIDS Technical Monitoring Committee-BC-CFE is responsible for oversight of the monitoring report. Motoi Matsukura writes and compiles the monitoring report. Guillaume Colley, Dr. Viviane Lima and Nada Gataric perform analysis of Indicators 5–13. James Nakagawa is responsible for publishing and editing. This report was conceived and guided by Dr. Julio Montaner.



BC Centre for Disease Control  
An agency of the Provincial Health Services Authority

**British Columbia Centre for Disease Control (BCCDC):** The BCCDC provides the data and outputs for Indicator 1 (Hiv Testing Episodes), Indicator 2 (Hiv Testing Rate), Indicator 3 (New Hiv Diagnoses), Indicator 4 (Stage of Hiv at Diagnosis) and Indicator 12 (AIDS-Defining Illness). The BCCDC is the single provincial agency that centralizes all HIV surveillance through the Public Health Microbiology and Reference Laboratory, which does more than 90% of all HIV screening tests in BC and all confirmatory testing. Theodora Consolacion and Dr. Jason Wong are responsible for outputs for Indicators 1–4.

## Other Data Sources:

The above databases were supplemented with:

- (I) The BC Vital Statistics database which was used to calculate Indicator 5. The Hiv Cascade of Care and Indicator 13. HIV-Related Mortality.
- (II) Linkage and preparation of the de-identified individual-level database used for calculating Indicator 5. The Hiv Cascade of Care was facilitated by the British Columbia Ministry of Health.
- (III) The Statistics Canada database: BC and HIV-positive population counts were acquired through the statistics Canada website to calculate HIV-specific mortality rates for Indicator 13. HIV-Related Mortality.

# Membership of the STOP HIV/AIDS Technical Monitoring Committee–BC-CfE

Dr. Rolando Barrios, *Chair*, BC-CfE

Kate Heath, BC-CfE

Bohdan Nosyk, BC-CfE

Viviane Dias Lima, BC-CfE

Irene Day, BC-CfE

Dr. Jason Wong, BCCDC

Dr. Mel Kradjen, BCCDC

Salman Klar, FHA

Corey Green, FNHA

Jennifer May-Hadford, IHA

James Haggerstone, NHA

Dr. Neora Pick, PHSA

Dr. Reka Gustafson, VCHA

Melanie Rusch, VIHA



# The Seek and Treat for Optimal Prevention (STOP) HIV/AIDS BC Provincial Program: A Note on Monitoring and Interpreting HIV Indicators

The Seek and Treat for Optimal Prevention (STOP) of HIV/AIDS programme is a provincial initiative to improve HIV diagnosis and care delivery in BC through increased HIV-specific funding to all HSDA's across BC. The STOP provincial programme is an expansion of a four-year STOP pilot project which was implemented in two Health Service Delivery Areas in March 2010; the Vancouver HSDA which bears the largest burden of the HIV epidemic in the province and the Northern Interior HSDA which bears a high burden of HIV-related mortality. The STOP pilot project demonstrated the urgent need for improved efforts in early diagnosis of HIV and timely initiation of antiretroviral therapy (ART) initiation.

The expansion to a province-wide programme was announced on November 30th 2013 by the BC Ministry of Health with roll out of funding beginning on April 1st, 2013. This funding is intended to be used in the implementation and evaluation of HIV-related diagnosis and care initiatives within individual HA's. Goals of the project include: 1. A reduction in the number of new HIV infections in BC; 2. Improvements in the quality, effectiveness, and reach of HIV prevention services; 3. An increase in early diagnosis of HIV; 4. A reduction in AIDS cases and HIV-related mortality.

The goals of HA-led STOP-funded initiatives are to work toward achieving these goals. To these ends some outcome measures or indicators of progress have been drafted that should be considered in the design and implementation phases of these initiatives.

# HIV Testing Episodes and Rates

In this section, the number of HIV test episodes and point of care (POC) HIV tests conducted each quarter in BC is shown. In general terms the goal is to increase the number of tests performed and to maximize testing efficiency. Test episodes are allocated by region according to where the test is performed.

## Indicator 1. HIV Testing Episodes

Figure 1.1 HIV Test Episodes for BC, 2010 Q1–2014 Q4




Figure 1.2 HIV Test Episodes by Gender and Prenatal Status for BC, 2010 Q1–2014 Q4<sup>1</sup>





Figure 1.3 HIV Test Episodes by Age Category for BC, 2010 Q1–2014 Q4 <sup>1,2</sup>



Figure 1.4 Point-of-Care HIV Tests for BC, 2010 Q4–2014 Q4



<sup>1</sup> Data Source: The BC Public Health Microbiology and Reference Laboratory (BCPHMRL) courtesy of the BC Centre for Disease Control (BCCDC). HIV screening tests conducted by the ViHA Laboratory are not included.

**Limitations:**

- i Repeat tests in individuals who test using various identifiers may not be identified and these individuals may be counted more than once.
- ii In Fraser Health, POC testing data are available from March 2011 forward. In Interior Health, POC testing data are available for May 2011 forward. For all other health authorities, POC testing data are available from the fourth quarter of 2010 forward.

<sup>2</sup> Testing does not include point of care tests.

Figure 1.5 HIV Test Episodes for BC by Health Authority, 2010 Q1–2014 Q4 <sup>1</sup>






Figure 1.6 HIV Test Episodes for Non-prenatal Females in BC by Health Authority, 2010 Q1–2014 Q4 <sup>1</sup>



Fraser Health	4.2	4.0	4.0	3.9	4.0	3.9	4.3	4.3	4.7	4.9	5.4	5.7	6.6	6.8	6.8	6.1	6.4	6.9	7.2	7.4
Interior Health	2.1	1.9	1.9	2.1	2.0	2.0	2.0	2.1	2.1	2.0	2.1	2.0	2.1	2.3	2.2	2.4	2.6	2.6	2.7	2.8
Island Health	2.0	1.8	1.8	1.8	1.9	1.7	1.8	1.7	1.9	1.8	1.9	2.0	2.1	2.2	2.1	2.1	2.3	2.3	2.4	2.4
Northern Health	1.0	1.0	0.9	0.9	1.0	0.9	1.0	1.0	1.2	1.1	1.2	1.2	1.3	1.4	1.3	1.3	1.6	1.5	1.5	1.5
Vancouver Coastal Health	6.6	6.6	6.6	6.3	6.8	6.4	7.1	8.0	9.5	9.8	11.1	11.2	13.6	14.8	14.0	13.6	15.8	17.9	20.0	19.6

Figure 1.7 HIV Test Episodes for Males in BC by Health Authority, 2010 Q1–2014 Q4 <sup>1</sup>



Fraser Health	4.5	4.4	4.4	4.4	4.6	4.3	4.7	4.6	5.3	5.1	5.5	5.7	6.6	7.0	6.7	6.5	6.9	7.1	7.3	7.5
Interior Health	2.0	1.8	1.8	1.9	2.0	1.8	1.8	2.0	2.0	1.9	2.1	2.1	2.2	2.3	2.3	2.4	2.6	2.8	2.7	2.9
Island Health	1.9	1.9	1.8	1.8	2.0	1.7	1.8	1.7	2.0	1.8	1.9	1.8	2.0	2.1	2.0	1.9	2.2	2.1	2.1	2.1
Northern Health	0.9	0.8	0.8	0.7	0.9	0.8	0.8	0.8	1.1	1.0	1.0	1.1	1.2	1.2	1.1	1.2	1.4	1.3	1.3	1.4
Vancouver Coastal Health	8.3	8.2	8.2	8.2	8.7	8.0	9.0	9.6	11.3	11.3	12.4	12.6	14.3	15.3	14.4	14.3	16.8	18.3	20.4	19.9

Figure 2.1 Rate of HIV Testing for BC and Health Authorities, 2009–2014 <sup>2</sup>




Figure 2.2 Rate of HIV Testing by Gender for BC, 2009–2014 <sup>2</sup>





Figure 2.3 Rate of HIV Testing by Age Category for BC, 2009–2014 <sup>2</sup>



<sup>2</sup> Testing does not include point of care tests.

# New HIV Diagnoses

Trends in HIV diagnoses by gender and exposure category are described. Interpreting HIV diagnoses must be done with consideration that trends are influenced by both changes in testing rate as well as changes in transmission rates. It is important to note that new HIV diagnoses cases and rates are not synonymous with HIV incidence as a person may have become infected with HIV long before they tested positive for HIV. However, as there is no reliable method for measuring HIV incidence we follow trends in HIV diagnoses.

## Indicator 3. New HIV Diagnoses

Figure 3.1 New HIV Diagnoses for BC, 2010 Q1–2014 Q4 <sup>3</sup>





Figure 3.2 New HIV Diagnoses for BC by Gender, 2010 Q1–2014 Q4 <sup>3</sup>



<sup>3</sup> Data Source: BCCDC. “By Provider Address” is graphed as dashed line in same colour.



Figure 3.3 New HIV Diagnoses for BC by Age Category, 2010 Q1–2014 Q4 <sup>3</sup>






Figure 3.4 New HIV Diagnoses for BC by Exposure Category, 2010 Q1–2014 Q2 <sup>3,4</sup>



<sup>3</sup> Data Source: BCCDC. “By Provider Address” is graphed as dashed line in same colour.

<sup>4</sup> MSM=men who have sex with men; IDU= injection drug user; HET=heterosexual. NIR=No identified risk/exposure. “By Provider Address” is graphed as dashed line in same colour.

Figure 3.5 New HIV Diagnoses for BC by Health Authorities, 2010 Q1–2014 Q4 <sup>3</sup>



<sup>3</sup> Data Source: BCCDC. "By Provider Address" is graphed as dashed line in same colour.



# Stage of HIV infection at diagnosis

Classification of stage of HIV infection, in the absence of information regarding recent testing history, is reliant on clinical information available at the time of diagnosis, including first CD4+ cell count, laboratory results suggestive of acute HIV infection, and clinical presentation with an AIDS-defining illness (Table 1). The benefits of Treatment as Prevention (TasP) are maximized when antiretroviral therapy (ART) is initiated at high CD4 cell counts. Accordingly, it is preferable that individuals newly diagnosed with HIV be in the early stages of HIV infection (stage 0 or 1) to allow for early ART initiation.

*N.B. Interpretation of stage of HIV infection at diagnosis should proceed with caution. Early increases in diagnosis at late stage (i.e., low CD4 counts) may represent a “catching up” of previously missed long term infected individuals rather than a trend toward diagnosis at later stage of infection.*

## Indicator 4. Stage of HIV Infection at Diagnosis

Table 1 Staging Classifications of Infection at Time of HIV Diagnosis Based on CDC HIV Surveillance Case Definitions

Stage	Criteria		
0	Laboratory criteria met for acute HIV infection, or previous negative or indeterminate HIV test within 180 days of first confirmed positive HIV test.		
1	Stage 0 not met	CD4 ≥500	and No AIDS case report
2a		CD4 350–499	
2b		CD4 200–349	
3		( CD4 <200	or AIDS case report )
Unknown		No available CD4	and No AIDS case report

Figure 4.1 Stage of HIV Infection at Diagnosis for BC, 2010–2013<sup>5</sup>





Figure 4.2 Stage of HIV Infection at Diagnosis by Gender for BC, 2010–2013<sup>5</sup>



	BC				Female				Male			
	2010	2011	2012	2013	2010	2011	2012	2013	2010	2011	2012	2013
Stage 0	52	63	53	49	8	3	6	3	44	60	47	45
Stage 1	66	53	51	56	12	8	6	9	54	44	44	47
Stage 2a	33	39	28	45	5	7	5	6	28	32	23	39
Stage 2b	34	39	30	30	12	8	6	3	22	31	24	27
Stage 3	76	68	58	71	22	13	5	9	54	55	53	62
Unknown	35	26	16	15	2	4	1	1	33	21	15	14
Total (n=)	296	288	236	266	61	43	29	31	235	243	206	234

Figure 4.3 Stage of HIV Infection at Diagnosis by Age Category for BC, 2010–2013 <sup>5</sup>





Figure 4.4 Stage of HIV Infection at Diagnosis by Exposure Category for BC, 2010–2013 <sup>5,6</sup>



	< 30 years				30–39 years				40–49 years				≥ 50 years				MSM				IDU				Heterosexual				Other				NIR/Unknown			
	2010	'11	'12	'13	'10	'11	'12	'13	'10	'11	'12	'13	'10	'11	'12	'13	'10	'11	'12	'13	'10	'11	'12	'13	'10	'11	'12	'13	'10	'11	'12	'13	'10	'11	'12	'13
Stage 0	19	14	18	19	16	25	18	15	13	19	10	10	4	5	7	5	37	51	42	37	6	5	4	7	8	7	7	4	0	0	0	1	1	0	0	
Stage 1	19	12	11	22	20	20	14	17	20	10	16	7	7	11	10	10	33	32	33	36	13	8	6	4	20	13	11	12	0	0	1	1	0	0	0	3
Stage 2a	7	11	4	12	14	12	4	13	9	11	11	10	3	5	9	10	20	25	17	31	6	5	6	5	7	7	5	7	0	2	0	2	0	0	0	
Stage 2b	5	6	7	4	9	8	7	10	11	12	10	9	9	13	6	7	15	20	16	22	5	3	6	0	12	15	8	8	2	1	0	0	0	0	0	
Stage 3	2	5	7	4	13	17	11	13	31	25	15	25	30	21	25	29	25	27	30	27	18	7	6	5	28	31	20	32	3	3	0	2	2	0	2	5
Unknown	11	6	7	1	13	10	3	4	10	5	2	4	1	5	4	6	22	15	10	4	4	6	1	4	7	2	1	4	1	1	1	3	1	2	3	0
Total (n=)	63	54	54	62	85	92	57	72	94	82	64	65	54	60	61	67	152	170	148	157	52	34	29	25	82	75	52	67	6	7	2	9	4	2	5	8

6 MSM=men who have sex with men; IDU= injection drug user; HET=heterosexual. NIR=No identified risk/exposure.

# Indicator 5. HIV Cascade of Care

The success of seek, test, treat and retain (STTR) strategies like STOP is reliant on early diagnosis of HIV, linking newly diagnosed HIV-positive persons with ongoing care, retaining persons in HIV-care; initiating ART based on best evidenced practices and maintaining optimal ART adherence to ensure a suppressed viral load. These stages of HIV-care can be summarized as: 1. HIV diagnosis, 2. Linked to HIV care, 3. Retained in HIV care, 4. On ART, 5. Adherent to ART and 6. Achieving a suppressed VL; collectively, they are referred to as the cascade of care. Leakage between any of these stages of HIV-care means a reduction in the potential of ART as a benefit to the HIV-positive individual and as an HIV transmission prevention method on a population level. Thus, when interpreting trends in the cascade of care, we strive to see increases along each step of the cascade of care (i.e. reduced attrition) with the ultimate goal being 100% within each stage of the cascade. Monitoring the Cascade of Care provides a picture as to where deficiencies lie in the delivery and uptake of HIV-care. In this section we present the cascade of care for the year 2012 in BC overall and stratified by sex and age for each Health Authority.

Figure 5.1 Estimated Cascade of Care for British Columbia, 2014 <sup>7</sup>





Figure 5.2 Estimated Cascade of Care for British Columbia by Gender, 2014 <sup>7</sup>



<sup>7</sup> Data is for the period 2014 Q1–2014 Q4.


Data Sources:

- i British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).
- ii Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).

Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider. If the most recent HA of residence is not updated then the designated HA may be incorrect.


NB: Transgender has been assigned to their biological sex.

Figure 5.3      Estimated Cascade of Care for British Columbia by Age Category, 2014 <sup>8</sup>



<sup>8</sup> Data is for the period 2014 Q1–2014 Q4.  
Data Sources:  
i British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).  
ii Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).  
Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider.  
If the most recent HA of residence is not updated then the designated HA may be incorrect.

Figure 5.4 Estimated Cascade of Care for British Columbia by MSM Status, 2014 <sup>9</sup>



<sup>9</sup> Data is for the period 2014 Q1–2014 Q4.

Data Sources:


- i British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).
- ii Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).

Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider. If the most recent HA of residence is not updated then the designated HA may be incorrect.

Recent updates to the DTP database have allowed for more comprehensive information on HIV risk group category. As a result, 2014 Q4 data may differ significantly from preceding reports in terms of total numbers ascribed to each risk group.



Figure 5.5 Estimated Cascade of Care for British Columbia by Age Category and MSM Status, 2014 <sup>9</sup>



<sup>9</sup> Data is for the period 2014 Q1-2014 Q4.


Data Sources:

- i British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).
- ii Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).

Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider. If the most recent HA of residence is not updated then the designated HA may be incorrect.

Recent updates to the DTP database have allowed for more comprehensive information on HIV risk group category. As a result, 2014 Q4 data may differ significantly from preceding reports in terms of total numbers ascribed to each risk group.

Figure 5.6 Estimated Cascade of Care for British Columbia by History of IDU, 2014 <sup>9</sup>



<sup>9</sup> Data is for the period 2014 Q1–2014 Q4.


Data Sources:

- i British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).
- ii Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).

Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider. If the most recent HA of residence is not updated then the designated HA may be incorrect.

Recent updates to the DTP database have allowed for more comprehensive information on HIV risk group category. As a result, 2014 Q4 data may differ significantly from preceding reports in terms of total numbers ascribed to each risk group.

Figure 5.7 Estimated Cascade of Care for British Columbia by Health Authority, 2014 <sup>9</sup>



<sup>9</sup> Data is for the period 2014 Q1–2014 Q4.

Data Sources:

- i British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).
- ii Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).

Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider. If the most recent HA of residence is not updated then the designated HA may be incorrect.

Recent updates to the DTP database have allowed for more comprehensive information on HIV risk group category. As a result, 2014 Q4 data may differ significantly from preceding reports in terms of total numbers ascribed to each risk group.

## Indicator 6. The Programmatic Compliance Score (PCS)

The Programmatic Compliance Score (PCS) is a summary measure of risk of future death, immunologic failure and virologic failure from all causes for people who are starting ART for the first time. It is composed of patient- and physician-driven effects. PCS scores range from 0–6 with higher scores indicative of poorer health outcomes and greater risk of death. Table 1 provides mortality, immunologic failure and virologic failure probabilities for given PCS scores. We interpret an individual with a  $PCS \geq 4$  as being 22 times more likely to die, almost 10 times more likely to have immunologic failure and nearly 4 times as likely to demonstrate virologic failure compared to those individuals with a PCS score of 0. A detailed description of how the PCS score is calculated and its validation can be found in the technical report. In short, PCS scores are calculated by summing the results (yes=1, no=0) of six un-weighted non-performance indicators based on IAS–USA treatment guidelines:

1. having <3 CD4 cell count tests in the first year after starting antiretroviral therapy (ART);
2. having <3 plasma viral load (VL) tests in the first year after starting ART;
3. not having drug resistance testing done prior to starting ART;
4. starting on a non-recommended ART regimen;
5. starting therapy with  $CD4 < 200$  cells/ $\mu$ L; and
6. not achieving viral suppression within 9 months since ART initiation.

In this section we provide PCS scores and their components over time for the province of BC. A decline to 0%, (i.e., all individuals having a score of 0) is the eventual goal.

Table 2. The Probability of Mortality, Immunologic Failure and Virologic Failure based on the Programmatic Compliance Score

Programmatic Compliance Score	Mortality Risk Ratio (95% Confidence Interval)	Immunologic Failure Risk Ratio (95% CI)	Virologic Failure Risk Ratio (95% CI)
0 (Best score)	1 (–)	1 (–)	1 (–)
1	3.81 (1.73–8.42)	1.39 (1.04–1.85)	1.32 (1.05–1.67)
2	7.97 (3.70–17.18)	2.17 (1.54–3.04)	1.86 (1.46–2.38)
3	11.51 (5.28–25.08)	2.93 (1.89–4.54)	2.98 (2.16–4.11)
4 or more (Worst score)	22.37 (10.46–47.84)	9.71 (5.72–16.47)	3.80 (2.52–5.73)

Reference: Lima VD, Le A, Nosyk B, Barrios R, Yip B, et al. (2012) Development and Validation of a Composite Programmatic Assessment Tool for HIV Therapy. *PLoS ONE* 7(11): e47859. doi:10.1371/journal.pone.0047859

Figure 6.1 PCS Components for BC, 2013 Q1–2014 Q4<sup>10</sup>





Figure 6.2 Historical Trends for PCS Score for BC, 2013 Q1–2014 Q4<sup>10,11</sup>



<sup>10</sup> Data Source: British Columbia Centre for Excellence Drug Treatment Program (DTP) Database.  
Limitations: CD4 cell count capture is approximately 80%.


<sup>11</sup> Each quarter's data is calculated as the sum of the 4 quarters leading up to it. e.g. 2013 Q1 is calculated from 2012 Q2 – 2013 Q1.  
NB: A score of 0 is the best score and a score of 4 or more is the worst score.

# Antiretroviral Uptake

In this section we present trends in ART uptake, the number and proportion of new HIV treatment initiations and the number of active and inactive DTP participants. Trends in ART uptake should be interpreted under the consideration of changing BC HIV treatment guidelines. BC HIV treatment guidelines are updated regularly by the BC-CfE Therapeutic Guidelines Committee and reflect those of the International AIDS Society. Most recent changes were made in 2012 and HIV treatment is now recommended for all HIV-positive adults regardless of CD4 cell count; as evidence demonstrates that early initiation of HIV treatment maximizes both the individual's health outcomes as well as the potential of ART as a form of HIV transmission prevention at a population level. As such, trends in the number and proportion of persons on ART and new ART starts (in both naïve and experienced persons) are expected to increase over time at higher CD4 cell counts.


## Indicator 7. New Antiretroviral Therapy Starts in BC

Figure 7 BC-CfE Drug Treatment Program Enrollment: New ART Participants in BC, 2013 Q1–2014 Q4 <sup>12</sup>



## Indicator 8. CD4 Cell Count at ART Initiation

Figure 8 CD4 Cell Count at ART Initiation of ART-Naïve DTP Participants in BC, 2013 Q1–2014 Q4 <sup>13</sup>



<sup>12</sup> Data Source: Drug Treatment Program Database  
Limitation: DTP participants are designated to an HA based on most current residence provided by the participant.


<sup>13</sup> Data Source: Drug Treatment Program Database  
Limitations: CD4 cell count data is approximately 80% complete.

## Indicator 9. Active and Inactive DTP Participants

Table 3. Distribution of People on ART for BC, 2014 Q4 <sup>14</sup>

		Fraser	Interior	Island	Northern	Vancouver Coastal	Total BC
Age	< 30	89	14	29	16	141	289
	30–39	250	49	86	50	524	959
	40–49	542	103	227	67	1170	2109
	≥ 50	783	262	456	93	2053	3648
Gender	Male	1282	331	647	137	3418	5816
	Female	382	97	151	89	470	1189
Exposure	MSM	519	114	202	28	1807	2671
	IDU	441	150	273	127	1133	2124
Total		1664	428	798	226	3888	7005

Figure 9 Active and Inactive DTP Participants for BC, 2013 Q1–2014 Q4 <sup>15</sup>



<sup>14</sup> Data Source: Drug Treatment Program Database  
Limitation: DTP participants are designated to an HA based on most current residence provided by the participant.

The recent update in DTP database allows improved classification of some individuals in the risk groups who were previously identified as unknown. This update is in effect from 2014Q4 and may result in noticeable changes of numbers in each risk group category compared to previous reports.

### Definitions:

'On antiretroviral therapy' defined as being on treatment in the current quarter

'Unknown/not stated' defined as being on treatment in the current quarter, and city of residence unknown

<sup>15</sup> Active DTP participants: are those who are prescribed one or more drugs in the last six months.


Inactive DTP Participants: Persons no longer prescribed drugs through the HIV/AIDS Drug Treatment Program in the last quarter.

# Antiretroviral Adherence Level

In this section we present trends in prescription refill adherence levels for individuals in their first year of treatment. Given that the benefits of ART are compromised in the presence of imperfect ART adherence, we expect to see the proportion of persons on ART achieving **near perfect adherence** (ie.  $\geq 95\%$ ) to increase with time. Furthermore, it is important that trends in the proportion of ART users achieving prescription refill adherence of  $\geq 95\%$  keep pace with new ART starts and increase among those continuing on ART.

## Indicator 10. Antiretroviral Adherence

Figure 10 Distribution of Individuals by Adherence Level in 1st Year of Therapy, Based on Pharmacy Refill Compliance for BC, 2013 Q1–2014 Q4 <sup>16</sup>




<sup>16</sup> Data Source: Drug Treatment Program Database  
Limitation: Prescription refill adherence is used as a proxy for patient adherence.



# Indicator 11. Resistance Testing and Results

In this section, we present trends in cumulative resistance testing by resistance category: **Suppressed** (where a DTP participant's viral load is too low to be genotyped); **Wild Type** (where no HIV treatment resistances were discovered), **Never Genotyped**, and Resistances to **one**, **two** or **three** HIV treatment classes. Resistance testing prior to ART initiation is recommended in the BC HIV treatment primary care guidelines. Thus, it is expected that trends over time should find all persons enrolled in the DTP to have been genotyped. Trends over time should also show an increase in the proportion of DTP participants achieving a suppressed status and an increase in resistance testing should not lead to an increase in the number of ART resistances occurring.

Figure 11 Cumulative Resistance Testing Results by Resistance Category for BC, 2013 Q1–2014 Q4 <sup>17</sup>




<sup>17</sup> Data Source: Drug Treatment Program Database

Limitation: DTP participants are designated to an HA based on most current residence provided by the participant.

## Indicator 12. AIDS-Defining Illness

Improvements in ART and the expansion of ART province-wide has led to very low numbers of recorded AIDS cases across BC. However, interpreting trends in AIDS cases is challenging as AIDS reporting is passive in BC and it is likely that they are under reported across all Health Authorities. In addition to under reporting, methods of reporting AIDS cases are inconsistent across HA's and do not truly reflect the current reality of new AIDS diagnoses. Efforts will need to be made to improve under and inconsistent reporting of AIDS cases across all HA's. The table below shows AIDS cases using three definitions. First, AIDS cases were defined as the number of physician-reported AIDS defining illness (ADI) in a given year. AIDS case reporting is a passive process and physicians can voluntarily report AIDS cases to the BCCDC or DTP. As such, we have plotted both **BCCDC reports** and **DTP reported AIDS cases**. We also show the proportion of persons **initiating ART with a CD4<200 cells/μL**.

Figure 12 AIDS Case Rate and Reports for BC, 2007–2014 <sup>18</sup>




<sup>18</sup> Data Source: DTP AIDS cases are obtained from the Drug Treatment Program Database; BCCDC AIDS cases are obtained from the BC-CDC; CD4<200 at ART initiation data came from the DTP database.

*Limitation:* AIDS case reporting was investigated using 3 definitions: First, using AIDS cases reported in AIDS case report forms from the DTP; Second, using AIDS cases reported via the BCCDC and third, using a CD4 cell count of <200 cells/μL at time of ART initiation using DTP data. AIDS case reporting is passive in BC, thus; AIDS case reporting is not well captured. The DTP sends out AIDS reporting forms to physicians annually. The BCCDC uses DTP AIDS case reports as well as physician AIDS case reports made directly to the BCCDC. Interpreting AIDS case reports should be done with these limitations in mind. AIDS data is updated annually as very few AIDS cases reports are reported in general and trends would be difficult to notice if reported quarterly.

## Indicator 13. HIV-Related Mortality

Evidence indicates that individuals who initiate treatment with recommended ART in a timely fashion may live near normal lifespans. Excess mortality among HIV positive persons is, therefore, an important measure of HIV care with a goal of minimizing HIV-related mortality in British Columbia.

Figure 13 HIV-Related Deaths by Year for BC, 2004–2011 <sup>19</sup>



<sup>19</sup> Data Source: BC Vital Statistics

*Limitation:*

1. DTP participants are designated to an HA based on most current residence provided by the participant.
2. Mortality data is updated annually.
3. The most recent available data was used.

# Appendices

Indicator 1: Test Episodes (thousands)		2010				2011				2012				2013				2014			
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
British Columbia		46.3	44.0	44.6	45.4	48.6	45.4	52.9	50.8	56.7	55.2	59.3	59.8	67.3	69.8	67.9	66.7	74.9	78.0	83.5	82.3
Gender	Female	28.0	26.3	27.0	26.9	28.7	26.2	28.0	29.0	32.4	31.6	33.8	33.9	38.2	39.3	38.4	37.6	41.6	43.1	46.0	46.0
	Male	17.6	17.1	16.9	17.0	18.2	16.6	18.2	18.8	21.6	21.1	22.8	23.4	26.2	27.9	26.5	26.2	30.0	31.6	33.8	33.7
	Other	0.7	0.7	0.6	0.6	0.6	0.6	0.6	0.6	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.2	0.3	0.3	0.3	0.2
Female (Prenatal)		12.1	11.0	11.8	12.0	12.9	11.3	11.8	11.9	13.0	11.9	12.0	11.9	12.5	11.7	12.0	12.0	12.9	11.9	12.3	12.4
Female (Non-prenatal)		15.9	15.2	15.3	14.9	15.8	14.9	16.2	17.1	19.4	19.7	21.8	22.1	25.7	27.5	26.4	25.6	28.7	31.2	33.7	33.6
Age	< 30	17.5	16.9	17.6	17.5	17.5	16.5	18.1	18.2	18.9	18.2	20.0	19.7	20.4	21.1	21.6	21.3	21.9	22.0	23.8	23.8
	30–39	15.4	14.2	14.4	14.1	15.9	13.9	14.8	14.8	17.3	16.3	16.8	16.6	19.2	19.2	18.9	18.4	21.4	20.6	21.5	20.9
	40–49	6.7	6.4	6.1	6.2	6.8	6.3	6.5	6.6	7.8	7.5	7.7	8.2	9.7	10.1	9.4	9.1	10.5	10.9	11.3	11.2
	≥ 50	5.7	5.6	5.5	5.7	6.2	5.7	6.3	7.0	8.8	9.1	10.8	11.7	15.2	16.9	15.2	15.2	17.9	21.4	23.5	24.0
POC HIV Tests					1.0	1.1	2.1	6.1	2.5	2.3	2.1	2.3	2.2	2.6	2.4	2.7	2.6	3.0	3.0	3.3	2.4
Fraser Health		13.0	12.3	12.5	12.5	13.1	12.2	13.0	13.0	14.4	14.2	15.1	15.6	17.9	18.1	17.9	17.0	18.0	18.6	19.1	19.4
Female (Non-prenatal)		4.2	4.0	4.0	3.9	4.0	3.9	4.3	4.3	4.7	4.9	5.4	5.7	6.6	6.8	6.8	6.1	6.4	6.9	7.2	7.4
Male		4.5	4.4	4.4	4.4	4.6	4.3	4.7	4.6	5.3	5.1	5.5	5.7	6.6	7.0	6.7	6.5	6.9	7.1	7.3	7.5
Interior Health		6.0	5.6	5.5	5.9	6.0	5.5	5.6	5.9	5.9	5.7	5.9	5.9	6.1	6.4	6.3	6.6	7.2	7.1	7.4	7.6
Female (Non-prenatal)		2.1	1.9	1.9	2.1	2.0	2.0	2.0	2.1	2.1	2.0	2.1	2.0	2.1	2.3	2.2	2.4	2.6	2.6	2.7	2.8
Male		2.0	1.8	1.8	1.9	2.0	1.8	1.8	2.0	2.0	1.9	2.1	2.1	2.2	2.3	2.3	2.4	2.6	2.8	2.7	2.9
Island Health		5.6	5.3	5.3	5.3	5.8	5.0	5.3	5.1	5.8	5.3	5.5	5.6	5.9	6.1	5.9	6.0	6.7	6.4	6.5	6.5
Female (Non-prenatal)		2.0	1.8	1.8	1.8	1.9	1.7	1.8	1.7	1.9	1.8	1.9	2.0	2.1	2.2	2.1	2.1	2.3	2.3	2.4	2.4
Male		1.9	1.9	1.8	1.8	2.0	1.7	1.8	1.7	2.0	1.8	1.9	1.8	2.0	2.1	2.0	1.9	2.2	2.1	2.1	2.1
Northern Health		2.9	2.6	2.7	2.5	3.0	2.7	2.9	2.8	3.4	3.1	3.2	3.3	3.7	3.6	3.5	3.5	4.2	3.8	3.8	3.9
Female (Non-prenatal)		1.0	1.0	0.9	0.9	1.0	0.9	1.0	1.0	1.2	1.1	1.2	1.2	1.3	1.4	1.3	1.3	1.6	1.5	1.5	1.5
Male		0.9	0.8	0.8	0.7	0.9	0.8	0.8	0.8	1.1	1.0	1.0	1.1	1.2	1.2	1.1	1.2	1.4	1.3	1.3	1.4
Vancouver Coastal Health		18.8	18.3	18.6	19.3	20.7	20.1	26.1	24.0	27.2	26.9	29.5	29.4	33.7	35.6	34.4	33.5	38.9	42.1	46.7	44.9
Female (Non-prenatal)		6.6	6.6	6.6	6.3	6.8	6.4	7.1	8.0	9.5	9.8	11.1	11.2	13.6	14.8	14.0	13.6	15.8	17.9	20.0	19.6
Male		8.3	8.2	8.2	8.2	8.7	8.0	9.0	9.6	11.3	11.3	12.4	12.6	14.3	15.3	14.4	14.3	16.8	18.3	20.4	19.9

## Indicator 2: Rate of HIV Testing per 100,000

		2009	2010	2011	2012	2013	2014
British Columbia		3674.4	3679.8	3778.7	4450.6	5164.6	5942.4
Fraser Health		3375.9	3365.6	3414.9	3860.5	4234.0	4494.5
Interior Health		2937.9	2989.0	3004.7	3077.8	3425.9	3858.0
Island Health		2755.7	2745.8	2711.1	2842.2	2985.1	3149.1
Northern Health		3592.9	3534.7	3712.1	4230.0	4557.6	4998.6
Vancouver Coastal Health		5242.9	5259.2	5555.6	7328.2	9232.3	11518.2
Gender	Female	4458.7	4443.5	4554.4	5292.5	6093.9	6869.9
	Male	2758.2	2795.9	2890.2	3535.2	4179.0	4953.7
Age	< 30	4043.4	4006.6	4038.9	4382.9	4784.3	5115.6
	30–39	8807.0	9005.9	9211.3	10184.5	11249.1	12225.8
	40–49	3356.5	3369.5	3506.2	4241.3	5321.4	6109.7
	≥ 50	1243.0	1284.7	1399.1	2181.6	3305.9	4418.6

Indicator 3: New HIV Diagnoses		2010				2011				2012				2013				2014			
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
British Columbia	By Client Residence	73	81	78	68	54	82	87	65	70	55	52	60	49	80	80	58	64	76	67	64
	By Provider Address	73	81	78	68	54	82	87	65	70	55	52	60	49	80	80	58	63	75	64	64
Gender	Female	17	20	14	11	6	19	11	7	9	10	5	5	6	13	8	5	13	9	13	11
	Male	56	61	64	57	48	63	76	58	61	45	47	55	43	67	72	53	49	65	51	53
Age	< 30	17	20	22	9	5	18	17	18	18	14	8	18	9	18	23	15	17	15	13	19
	30–39	25	18	23	20	18	30	30	13	16	17	11	10	16	25	18	11	17	21	26	16
	40–49	23	29	19	24	18	22	22	19	20	11	19	19	12	14	21	20	14	14	7	15
	≥ 50	8	14	14	15	13	12	18	15	16	13	14	13	12	23	18	12	15	25	18	14
Exposure	MSM	39	36	45	33	33	43	56	38	42	34	37	36	29	46	45	38	35	42	–	–
	IDU	14	16	12	10	8	11	12	3	14	7	2	6	4	7	5	9	9	5	–	–
	HET	18	25	18	22	12	23	19	21	14	12	11	15	15	20	24	9	16	18	–	–
	Other	2	2	1	1	1	3	0	3	0	1	0	1	0	3	5	0	0	1	–	–
	NIR/Unknown	0	2	2	2	0	2	0	0	0	1	2	2	1	4	1	2	3	9	–	–
Fraser Health	By Client Residence	17	19	19	17	12	18	15	9	11	10	10	14	8	14	23	19	15	11	16	16
	By Provider Address	14	15	13	15	10	20	9	8	10	5	7	8	9	8	14	15	11	10	12	13
Interior Health	By Client Residence	4	1	3	3	1	4	3	3	5	5	0	2	1	4	4	4	3	4	4	5
	By Provider Address	4	1	2	3	1	3	2	3	5	5	0	2	1	5	4	4	3	2	4	5
Island Health	By Client Residence	6	13	8	6	5	2	7	7	6	3	5	12	4	9	10	7	6	4	7	8
	By Provider Address	6	12	8	5	5	3	6	6	3	3	5	12	5	9	10	7	6	4	8	8
Northern Health	By Client Residence	4	3	7	2	4	10	5	5	5	4	3	0	3	8	3	3	2	5	4	2
	By Provider Address	4	3	6	2	4	9	5	6	5	4	3	0	3	8	3	3	2	5	3	2
Vancouver Coastal Health	By Client Residence	41	45	41	40	32	48	57	41	43	33	33	32	31	45	40	25	37	49	33	33
	By Provider Address	45	50	49	43	34	47	65	42	47	38	37	38	31	50	49	29	41	54	37	36

#### Indicator 4: Stage of HIV Infection at Baseline

	British Columbia				Female				Male				< 30 years				30–39 years				40–49 years			
	'10	'11	'12	'13	'10	'11	'12	'13	'10	'11	'12	'13	'10	'11	'12	'13	'10	'11	'12	'13	'10	'11	'12	'13
Stage 0	52	63	53	49	8	3	6	3	44	60	47	45	19	14	18	19	16	25	18	15	13	19	10	10
Stage 1	66	53	51	56	12	8	6	9	54	44	44	47	19	12	11	22	20	20	14	17	20	10	16	7
Stage 2a	33	39	28	45	5	7	5	6	28	32	23	39	7	11	4	12	14	12	4	13	9	11	11	10
Stage 2b	34	39	30	30	12	8	6	3	22	31	24	27	5	6	7	4	9	8	7	10	11	12	10	9
Stage 3	76	68	58	71	22	13	5	9	54	55	53	62	2	5	7	4	13	17	11	13	31	25	15	25
Unknown	35	26	16	15	2	4	1	1	33	21	15	14	11	6	7	1	13	10	3	4	10	5	2	4
Total	296	288	236	266	61	43	29	31	235	243	206	234	63	54	54	62	85	92	57	72	94	82	64	65
	≥ 50 years				MSM				IDU				Heterosexual				Other Exposure				NIR/Unknown			
	'10	'11	'12	'13	'10	'11	'12	'13	'10	'11	'12	'13	'10	'11	'12	'13	'10	'11	'12	'13	'10	'11	'12	'13
Stage 0	4	5	7	5	37	51	42	37	6	5	4	7	8	7	7	4	0	0	0	1	1	0	0	0
Stage 1	7	11	10	10	33	32	33	36	13	8	6	4	20	13	11	12	0	0	1	1	0	0	0	3
Stage 2a	3	5	9	10	20	25	17	31	6	5	6	5	7	7	5	7	0	2	0	2	0	0	0	0
Stage 2b	9	13	6	7	15	20	16	22	5	3	6	0	12	15	8	8	2	1	0	0	0	0	0	0
Stage 3	30	21	25	29	25	27	30	27	18	7	6	5	28	31	20	32	3	3	0	2	2	0	2	5
Unknown	1	5	4	6	22	15	10	4	4	6	1	4	7	2	1	4	1	1	1	3	1	2	3	0
Total	54	60	61	67	152	170	148	157	52	34	29	25	82	75	52	67	6	7	2	9	4	2	5	8

Indicator 5: <b>HIV Cascade of Care</b>			DIAGNOSED	LINKED	RETAINED	ON ART	ADHERENT	SUPPRESSED
British Columbia			9661	8710	7428	6930	6328	5399
Age Category	< 30		491	331	282	256	220	181
	30–39		1308	1169	997	885	775	652
	40–49		2775	2542	2151	2020	1801	1498
	≥ 50		5079	4667	3998	3769	3532	3068
Age Category and MSM Status	MSM	< 30	106	91	79	73	62	51
		30–39	336	314	280	254	226	195
		40–49	764	743	695	655	604	535
		≥ 50	1875	1827	1710	1639	1549	1421
	Non-MSM	< 30	54	52	47	40	32	25
		30–39	379	363	335	300	252	197
		40–49	895	859	800	755	632	490
		≥ 50	1397	1351	1263	1176	1076	859
	Unknown	< 30	332	188	156	143	126	105
		30–39	592	492	382	331	297	260
		40–49	1115	940	656	610	565	473
		≥ 50	1808	1489	1026	954	907	788
Gender	Male		7900	7182	6132	5750	5303	4576
	Female		1761	1528	1297	1180	1025	823
Injection Drug Use	IDU		2530	2437	2301	2157	1889	1486
	Non-IDU		4227	4092	3796	3587	3338	2973
	Unknown		2903	2180	1331	1186	1101	940
MSM Status	MSM		3081	2975	2765	2621	2441	2202
	Non-MSM		2725	2626	2444	2271	1992	1571
	Unknown		3854	3109	2219	2038	1895	1626
Health Authority	Fraser Health		1983	1891	1746	1651	1478	1284
	Interior Health		557	538	461	430	390	314
	Island Health		921	885	830	786	710	560
	Northern Health		278	258	238	220	196	134
	Vancouver Coastal Health		4660	4456	4052	3842	3553	3107

Indicator 6: **Programmatic Compliance Score (PCS)**

	2013				2014			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
< 3 CD4 Tests	17.5%	18.4%	17.9%	18.2%	21.9%	25.2%	22.7%	21.4%
< 3 Viral Load Tests	7.7%	8.7%	9.3%	8.4%	8.5%	7.9%	6.7%	6.1%
No Baseline Genotype	6.4%	5.6%	5.5%	5.3%	4.1%	4.0%	4.3%	2.2%
Baseline CD4 < 200 cells/μL	21.3%	20.6%	21.2%	20.5%	21.9%	24.1%	25.1%	24.2%
Non-Recommended ART	2.3%	2.8%	6.2%	9.4%	10.7%	11.3%	7.8%	3.6%
Non Viral suppression at 9 Mo.	36.0%	37.4%	37.7%	34.9%	35.5%	36.0%	33.2%	31.2%
PCS Score: 0	209	205	176	160	139	121	141	159
PCS Score: 1	149	138	130	137	125	131	135	112
PCS Score: 2	64	72	71	62	68	65	67	63
PCS Score: 3	39	40	32	26	24	24	22	19
PCS Score: 4 or more	8	7	10	10	10	12	9	6
<b>Total (n=)</b>	<b>469</b>	<b>462</b>	<b>419</b>	<b>395</b>	<b>366</b>	<b>353</b>	<b>374</b>	<b>359</b>

Indicator 7: **New DTP ARV Participants**

First Starts	97	92	112	75	106	91	78	81
Experienced Starts	91	111	114	127	116	133	137	110

**Indicator 8: CD4 Cell Count at ART Initiation for ARV-Naïve DTP Participants**

CD4 ≥ 500	21	35	31	29	34	40	29	29
CD4 350–499	29	16	20	18	20	21	15	15
CD4 200–349	25	18	28	15	30	11	12	17
CD4 50–199	15	13	23	11	13	16	13	12
CD4 < 50	7	8	9	1	8	2	8	6
<i>CD4 Median (cells/μL)</i>	<i>360</i>	<i>381</i>	<i>300</i>	<i>430</i>	<i>360</i>	<i>480</i>	<i>410</i>	<i>400</i>
<b>Total (n=)</b>	<b>97</b>	<b>90</b>	<b>111</b>	<b>74</b>	<b>105</b>	<b>90</b>	<b>77</b>	<b>79</b>

**Indicator 9: Active and Inactive DTP Participants**

Active DTP Participants	6497	6577	6648	6721	6810	6899	6954	7005
Inactive DTP Participants	1107	1094	1109	1111	1117	1122	1135	1155

**Indicator 10: Antiretroviral Adherence**

≥ 95%	99	88	63	68	76	70	92	81
80% to < 95%	21	20	24	13	12	13	15	14
40% to < 80%	6	9	8	10	8	10	13	8
< 40%	2	1	1	2	1	1	1	0
<b>Total (n=)</b>	<b>128</b>	<b>118</b>	<b>96</b>	<b>93</b>	<b>97</b>	<b>94</b>	<b>121</b>	<b>103</b>

**Indicator 11: Resistance Testing and Results**

Suppressed	4562	4582	4665	4505	4968	4906	5090	4881
Wild Type	943	901	863	823	753	711	682	611
Never Genotyped	84	79	83	58	65	61	49	52
1-Class	175	185	168	164	148	148	144	135
2-Class	43	50	38	33	26	28	24	21
3-Class	9	9	10	5	4	5	4	2
<b>Total (n=)</b>	<b>5816</b>	<b>5806</b>	<b>5827</b>	<b>5588</b>	<b>5964</b>	<b>5859</b>	<b>5993</b>	<b>5702</b>

**Indicator 12: AIDS-Defining Illness**

		2007	2008	2009	2010	2011	2012	2013	2014
CD4 < 200 at ART initiation	Cases	224	194	155	138	115	96	90	84
	<i>Rate per 100,000</i>	<i>5.2</i>	<i>4.5</i>	<i>3.5</i>	<i>3.1</i>	<i>2.6</i>	<i>2.1</i>	<i>2.0</i>	<i>1.8</i>
AIDS Cases (DTP Reports)	Cases	134	130	110	103	81	67	68	48
	<i>Rate per 100,000</i>	<i>3.1</i>	<i>3.0</i>	<i>2.5</i>	<i>2.3</i>	<i>1.8</i>	<i>1.5</i>	<i>1.5</i>	<i>1.0</i>
AIDS Cases (BCCDC Reports)	Cases	143	142	124	111	90	73	56	–
	<i>Rate per 100,000</i>	<i>3.3</i>	<i>3.2</i>	<i>2.8</i>	<i>2.5</i>	<i>2.0</i>	<i>1.6</i>	<i>1.2</i>	–

**Indicator 13: HIV-Related Mortality**

	2004	2005	2006	2007	2008	2009	2010	2011
British Columbia	105	146	142	100	79	63	54	59
Per 100 HIV+ Population	1.03	1.40	1.34	0.93	0.72	0.56	0.47	0.50
Per 100,000 Population	2.50	3.43	3.29	2.28	1.80	1.41	1.19	1.29